Justin Walsh
Stock Analyst at Jones Trading
(1.86)
# 3,032
Out of 4,732 analysts
31
Total ratings
36.67%
Success rate
-7.78%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $4.64 | +287.93% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $12.69 | +230.97% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $1.72 | - | 2 | Oct 11, 2024 | |
| BLRX BioLineRx | Initiates: Buy | $2 | $0.10 | +1,870.44% | 1 | Sep 4, 2024 | |
| LNTH Lantheus Holdings | Maintains: Buy | $105 → $146 | $91.47 | +59.62% | 7 | Jul 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $6.16 | +273.38% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $3.43 | +541.40% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $4.93 | +224.54% | 1 | May 10, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $20 | $3.09 | +547.25% | 1 | Apr 17, 2024 | |
| CTSO Cytosorbents | Reinstates: Buy | $4 | $1.03 | +288.35% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.89 | +592.04% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.33 | +1,253.38% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $4.83 | +9,009.73% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $1.17 | +6,310.26% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $33.85 | -40.92% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $3.29 | +5,979.03% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.60 | +284.62% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $4.10 | +19,412.20% | 1 | Sep 2, 2021 |
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $4.64
Upside: +287.93%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $12.69
Upside: +230.97%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.72
Upside: -
BioLineRx
Sep 4, 2024
Initiates: Buy
Price Target: $2
Current: $0.10
Upside: +1,870.44%
Lantheus Holdings
Jul 25, 2024
Maintains: Buy
Price Target: $105 → $146
Current: $91.47
Upside: +59.62%
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $6.16
Upside: +273.38%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.43
Upside: +541.40%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.93
Upside: +224.54%
Achieve Life Sciences
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.09
Upside: +547.25%
Cytosorbents
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $1.03
Upside: +288.35%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $2.89
Upside: +592.04%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $1.33
Upside: +1,253.38%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $4.83
Upside: +9,009.73%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $1.17
Upside: +6,310.26%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $33.85
Upside: -40.92%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $3.29
Upside: +5,979.03%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $2.60
Upside: +284.62%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $4.10
Upside: +19,412.20%